Key Highlights
- Cooper Companies traded at US$54.75, against a consensus target of US$69.57.
- The median target of US$66 implies roughly +20.5% upside from the current price.
- Targets span US$58 to US$103, framing the range of analyst opinion.
- The consensus implies +27.1% upside, reflecting the balance of current analyst views.
Cooper Companies (NASDAQ:COO) traded at US$54.75 as of 8 October 2026, against an analyst consensus price target of US$69.57, an implied upside of approximately +27.1%.
What Is the Latest Analyst Price Target?
A data provider screener, as at 8 October 2026, puts the mean analyst price target at $69.57 and the median at $66. The low is $58 and the high is $103. Compared with the $54.75 price, the mean implies potential upside of 27.1%.
The mean sits more than $3 above the median, which means a few high forecasts, notably the $103 top end, are pulling the average upward. The median of $66 is a more conservative guide, and it still implies roughly 20.5% potential upside. Importantly, the lowest target of $58 is above the share price, by about 5.9%. On this evidence, no forecaster in the data set expects the shares to be lower, though targets may lag a share price that has been under pressure.
What Are Analysts Saying?
The provider's consensus rating for Cooper Companies is Buy. Individual broker actions, analyst numbers and index membership were not part of this week's verified data set, so none is described.
The distribution of targets is the main takeaway. A range of $45 between low and high, and a mean that exceeds the median, suggest a cluster of moderate forecasts with a few bullish outliers. When the share price sits below the whole range, it is worth considering whether the market is signalling concerns that analysts are slower to price in.
What Could Help the Stock Reach the Price Target?
Cooper operates through two principal segments, CooperVision, which makes contact lenses, and CooperSurgical, which supplies products for fertility and women's healthcare. The company has positioned itself in markets with structural Demand drivers, including rising rates of short-sightedness and demand for assisted reproduction.
If analysts prove correct, growth in daily disposable and specialty lenses, including products aimed at slowing myopia progression, could support CooperVision. Fertility services and diagnostics may provide steady growth for CooperSurgical. Margin improvement through cost control, operational efficiency and portfolio decisions could also assist, and a depressed share price leaves room for rerating if execution improves.
What Could Prevent the Stock Reaching the Target?
The contact lens market is competitive and relatively concentrated, and pricing pressure or share losses to rivals could hurt results. Consumer demand may soften if households economise on elective purchases.
CooperSurgical's performance depends on fertility treatment volumes, which can be sensitive to economic conditions and reimbursement policy. The shares trading below the lowest target may also suggest that investors doubt the pace of recovery, and the gap between mean and median shows that some of the optimism rests on a small number of high forecasts.
What Should Investors Watch Next?
The next quarterly results and guidance should show whether lens volumes and pricing are stabilising and whether fertility demand is holding up. Investors will probably focus on organic growth, gross margin and any update on cost savings.
Structural catalysts include uptake of myopia management lenses, innovation in daily disposables, strategic portfolio reviews and Capital allocation, including potential repurchases.
The Case Analysts Are Making on Cooper Companies
Cooper Companies (COO) was priced at US$54.75 against a consensus target of US$69.57, an implied upside of approximately +27.1%. The median target of US$66 and the range of US$58 to US$103 frame the debate among analysts.






Please wait processing your request...